An expert panel discussed the systemic and policy barriers to the uptake of biosimilars.
Skylar Jeremias
Advertisement
Skylar is an associate editorial director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
Articles by Skylar Jeremias
The results are in line with earlier studies, and the current review found a link with bladder cancer and lung cancer.
Investigators say that inconsistencies in the way rare diseases are defined contribute to misdiagnoses, delayed treatment, and other ills that could be addressed with global standards.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
3
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
4
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
5